Cortexyme to Present New GAIN Trial Data at AD/PD 2022
Cortexyme, Inc. (Nasdaq: CRTX) will participate in the AD/PD 2022 International Conference on Alzheimer’s and Parkinson’s Diseases from March 15-20, 2022, in Barcelona, Spain. Chief Medical Officer Michael Detke will present new results from the GAIN Trial, focusing on the role of P. gingivalis in Alzheimer’s disease. This presentation will highlight biomarker data and the efficacy of the company’s gingipain inhibitor in slowing cognitive decline among patients. Additional findings will be shared throughout 2022.
- None.
- None.
New data expands evidence base of role of P. gingivalis in Alzheimer’s disease
Discussion to include new biomarker results and correlations between biomarkers and clinical outcomes
AD/PD 2022 Abstract Details
Title: Data from the Phase 2/3 GAIN Trial of COR388 (Atuzaginstat) for the Treatment of Mild-Moderate Alzheimer’s Disease
-
Presenter:
Michael Detke , MD, PhD, Cortexyme’s chief medical officer.
-
Authors:
Michael Detke 1,Marwan Sabbagh 2,Mark Ryder 3,Joanna Bolger 1,Dave Hennings 1,Vladimir Skljarevski 1,Shirin Kapur 1,Debasish Raha 1,Florian Ermini 1,Mai Nguyen 1,Ursula Haditsch 1,Kim Perry 4,Kelly Ritch 5,Suzanne Hendrix 6,Sam Dickson 6, Hatice Hasturk7,Sarah Horine 1,Craig Mallinckrodt 1,Leslie Holsinger 1,Casey Lynch 1, andStephen Dominy 1.
-
Access: Cortexyme’s AD/PD 2022 presentation will take place on
Sunday, March 20, 2022 , at10:50 a.m. CET (5:50 a.m. EDT ) and will be accessible to AD/PD 2022 registered meeting attendees in-person and on its virtual platform. The company will issue a news release summarizing highlights of the presentation and post the presentation to the science section of its corporate website shortly after the conclusion of the presentation.
1
About
Forward-Looking Statements
Statements in this news release contain “forward-looking statements” that are subject to substantial risks and uncertainties. Forward-looking statements contained in this news release may be identified by the use of words such as “outcomes,” “intends,” “will,” “estimate,” “potential,” “correlations,” “reinforces” or other similar words. Examples of forward-looking statements include, among others, the strategic development path for atuzaginstat; its business plans, internal and external development of the pipeline, strategy, planned FDA submissions and clinical trials and timeline, prospects, and milestone expectations; the timing and success of the company’s clinical trials and related data, including plans and the ability to initiate, conduct and/or complete current and additional studies; the timing of announcements and updates relating to its clinical trials and related data; the potential therapeutic benefits, safety and efficacy of the company’s product candidate or library of compounds; and statements about its ability to obtain, and the timing relating to, further development of atuzaginstat and other programs or indications, regulatory submissions and interactions with regulators, and related response and decisions, and approvals with respect to the company’s drug product candidate. Forward-looking statements are based on Cortexyme’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict and could cause actual results to differ materially from what the company expects. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to, the risks and uncertainties described in the section titled “Risk Factors” in Cortexyme’s Annual Report on Form 10-K filed with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20220314005261/en/
Vice President,
ir@cortexyme.com
Source:
FAQ
What is Cortexyme presenting at the AD/PD 2022 conference?
When is Cortexyme's presentation at the AD/PD 2022 conference?
What are the key findings from the GAIN Trial?
Where is the AD/PD 2022 conference being held?
What is the significance of P. gingivalis in Alzheimer's disease?